BeiGene to Open Doors at Flagship U.S. Manufacturing and Clinical R&D Center

BeiGene will mark the grand opening of an $800 million manufacturing and clinical R&D center at the Princeton West Innovation Campus in Hopewell, N.J., on Tuesday, July 23 at 11:00 a.m.

Governor Phil Murphy and Hopewell Mayor Courtney Peters-Manning among other dignitaries will join John V. Oyler, co-founder, chairman and CEO of BeiGene at the grand opening at Princeton West Innovation Campus located at 311 Pennington Rocky Hill Rd.

CLICK HERE TO SIGN UP FOR THE FREE TAPINTO.NET NEWSLETTER

The new campus provides 400,000 square feet of dedicated clinical- and commercial-stage biologics manufacturing space with the ability to add 700,000 square feet over time.

With the opening of this facility, BeiGene, a global oncology company dedicated to changing how cancer is treated, will bring approximately 130 skilled jobs to the Hopewell area. BeiGene selected the Hopewell Valley for its late-stage clinical development and manufacturing facility because of its central location and the rich scientific, development and manufacturing talent.

Currently, BeiGene’s BTK inhibitor, BRUKINSA (zanubrutinib) and PD-1 inhibitor, are approved in the U.S. as well as TEVIMBRA (tislelizumab-jsgr). BeiGene was founded in 2010 and has a growing global team of more than 10,000 colleagues across five continents.

For more local news, visit TAPinto.net